Navigation Links
EpiCept Announces Presentation of New Ceplene(TM) Data at the 49th Annual Meeting of the American Society of Hematology
Date:12/3/2007

Session Name: Lymphocytes, Natural Killer, and Dendritic Cells II.

Presenter: Ana I. Romero, et al.; University of Goteborg, Goteborg,

Sweden.

A third abstract developed by EpiCept investigators entitled "Impact on Quality of Life of Postconsolidation Immunotherapy with Histamine Dihydrochloride and Interleukin-2 in Acute Myelogenous Leukemia" appeared in the November edition of Blood, The Journal of The American Society of Hematology. This paper demonstrated that patients treated with Ceplene in conjunction with low dose interleukin-2 had an equivalent quality of life compared to the current standard of care, which is no treatment, in the pivotal trial.

EpiCept also announced today that it is providing an educational grant in support of a CME-certified Symposium for clinicians and scientists specializing in hematology and oncology entitled "Improving Outcomes in Acute Myeloid Leukemia." The event will take place on Friday, December 7, 2007 beginning at 7:00 p.m. in Room B211-212, Building B, Level 2 at the Georgia World Congress Center in Atlanta, Georgia. Additional information on the Symposium is available at http://www.dwrite.com/ASH2007.

About Ceplene

Ceplene is EpiCept's registration-stage compound for the treatment of AML. Ceplene is designed to protect lymphocytes responsible for immune-mediated destruction of residual leukemic cells. Laboratory research has demonstrated that Ceplene reduces formation of oxygen radicals from phagocytes, inhibiting NADPH oxidase and protecting IL-2-activated NK-cells and T-cells.

About EpiCept Corporation

EpiCept is focused on unmet needs in the treatment of pain and cancer. The Company's broad portfolio of pharmaceutical product candidates includes several pain therapies in clinical development and a lead oncology compound for AML with demonstrated efficacy in a Phase III trial; a marketing authorization applicati
'/>"/>

SOURCE EpiCept Corporation
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine news :

1. EpiCept Corporation to Present at the 2007 BIO InvestorForum
2. EpiCept to Present Preclinical Studies of EPC2407 in Combination With Anti-Angiogenic and Chemotherpeutic Agents at the AACR-NCI-EORTC International Conference
3. EpiCept Corporation To Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
4. EpiCept To Host Third Quarter 2007 Conference Call and Webcast on November 7, 2007
5. EpiCept Corporation Reports Third Quarter 2007 Operating and Financial Results
6. EpiCept Corporation to Present at the BMO Capital Markets 2007 Focus on Healthcare Conference
7. Patient Enrollment Completed in Phase IIb Trial of EpiCept(TM) NP-1 in Diabetic Peripheral Neuropathy
8. HHS Announces $75 Million in Supplemental Funding to States for Pandemic Flu Preparedness
9. CRC Health Group Announces Acquisition of Bayside Marin Recovery Center, San Rafael
10. UHW Announces: Antelope Valley Hospital Caregivers and Board Vote to Ratify First Union Contract With SEIU UHW-West
11. HEI, Inc. Announces Sale of RFID Division Assets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/19/2013)... People in Minnesota have a great option to get in ... Day Fat Loss Formula. The best part is people ... home. The product sells for $135 dollars and is an ... http://altmanfitness.com/28-day-fat-loss-formula/ , “Bikini season is almost here. People ... using the 28 Day Fat Loss Formula they will be ...
(Date:5/19/2013)... City, Utah (PRWEB) May 19, 2013 ... information on small business health insurance . ... to traditional employer sponsored health benefits, is the ... and health reimbursement arrangements . , ... start-ups, and the self-employed intrinsically know the value ...
(Date:5/19/2013)... May 19, 2013 These molecular ... US, UK, Spain, Japan, Italy, Germany and France:, ... molecular diagnostics laboratory practice, as well as key ... significant market impact during the next five years. ... and biochip technologies, test formats, detection methodologies, trends ...
(Date:5/19/2013)... (PRWEB) May 19, 2013 Americans live ... to the newest American Veterinary Medical Association (AVMA) U.S. ... American dog owners consider their dog a member of ... had said as much five years earlier. , According ... value of the national income dedicated to pets has ...
(Date:5/19/2013)... Las Vegas, Nevada (PRWEB) May 19, 2013 ... travel agency , is proud to announce the launch ... Music Awards at the MGM Grand on 5/19/2013. Consumers ... the all new special pricing available on VegasHotelEscapes.com's website. ... guarantee that they beat any competitors price. , Vegas ...
Breaking Medicine News(10 mins):Health News:Zane Benefits Publishes New Information on Small Business Health Insurance 2Health News:Zane Benefits Publishes New Information on Small Business Health Insurance 3Health News:Molecular Diagnostics Market - US, UK, Spain, Japan, Italy, Germany & France Analysis in New Research Report at ReportsnReports.com 2Health News:Molecular Diagnostics Market - US, UK, Spain, Japan, Italy, Germany & France Analysis in New Research Report at ReportsnReports.com 3Health News:Molecular Diagnostics Market - US, UK, Spain, Japan, Italy, Germany & France Analysis in New Research Report at ReportsnReports.com 4Health News:Dogs Becoming Part of the Family: Dog Bite Injuries Decreasing 2Health News:Dogs Becoming Part of the Family: Dog Bite Injuries Decreasing 3
... Feb. 10 During scheduled visits to Members of ... Homecare and its members will urge Congress and the ... the Medicare Anti-Fraud Legislative Plan. Developed by the ... tough, effective measures to stop waste, fraud and abuse ...
... researchers say , , TUESDAY, Feb. 10 (HealthDay News) -- ... even bother to use them because they,re difficult to ... are allowing the brain to communicate directly with artificial ... banana and fold laundry. , "In the simplest terms, ...
... even if you stop taking the drug, study finds , , ... aspirin or other nonsteroidal anti-inflammatory drugs (NSAIDs) appears to reduce ... cancer. , That,s the conclusion of a new study of ... clear, and arguably proven, that NSAID drugs do interfere with ...
... of Potential Surrogate Endpoints of Long-Term Survival in Prostate ... distant metastases 3 years after the start of treatment ... with early prostate cancer. , Prostate cancer is a ... history of the disease makes evaluation of new therapies ...
... percent as a result of My Health programLOS ... Institute (IBI) and the National Business Coalition on ... the 2009 IBI/NBCH Healthy Workforce Productivity Award at ... 9-11 in Los Angeles. The award, sponsored by ...
... to have an effect on whether a patient with terminal ... by researchers at Beth Israel Deaconess Medical Center (BIDMC). Published ... the American Geriatrics Society ( JAGS ), the findings ... services less frequently than do whites and Hispanics. , According ...
Cached Medicine News:Health News:American Association for Homecare Proposes to Congress a Medicare Anti-Fraud Action Plan that Includes Increased Penalties, Site Inspection, and Tough Standards 2Health News:American Association for Homecare Proposes to Congress a Medicare Anti-Fraud Action Plan that Includes Increased Penalties, Site Inspection, and Tough Standards 3Health News:American Association for Homecare Proposes to Congress a Medicare Anti-Fraud Action Plan that Includes Increased Penalties, Site Inspection, and Tough Standards 4Health News:New Technology May Boost Artificial Arms 2Health News:Long-Term Aspirin Use Seems to Protect Against Colorectal Lesions 2Health News:Long-Term Aspirin Use Seems to Protect Against Colorectal Lesions 3Health News:Also in the Feb. 10 JNCI 2Health News:Also in the Feb. 10 JNCI 3Health News:Also in the Feb. 10 JNCI 4Health News:Also in the Feb. 10 JNCI 5Health News:Nationwide Receives IBI/NBCH Healthy Workforce Productivity Award 2Health News:Nationwide Receives IBI/NBCH Healthy Workforce Productivity Award 3Health News:Study finds race and ethnicity affect use of hospice services among patients with advanced cancer 2
(Date:5/17/2013)... BOSTON , May 17, 2013  TechAtlas ... update for their competitive landscape map for the ... highlights over 90 international companies with drugs and ... addressing CKD and its sequelae. ... include: , hypertension - renal denervation ...
(Date:5/17/2013)... Fuse Science, Inc. (OTCQB: DROP), ( www.fusescience.com ) ... new, patent-pending technologies poised to redefine how consumers receive energy, ... a business update teleconference and webcast for shareholders and the ... 4:30 PM ET. Fuse Science, Inc. CEO, ... and will be joined by Rubin Hanan ...
(Date:5/17/2013)... -- Sanofi (EURONEXT: SAN and NYSE: SNY ) announced ... , examining the selective JAK2 inhibitor SAR302503 for myelofibrosis ... The primary endpoint assessed the proportion of patients achieving ... in previous trials, the most common adverse events were ... presented at an upcoming medical congress. ...
Breaking Medicine Technology:TechAtlas Group Releases Innovative Chronic Kidney Disease Landscape Map 2Fuse Science, Inc. to Hold Business Update Webcast and Teleconference on May 22nd 2Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 2Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 3Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 4Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 5Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 6
6 mm x 23 mm blunt, double-edged blade. Flat handle....
7 mm blade, angled right. Flat handle....
5 mm x 8 mm "D" shaped knife. Flat handle. Designated most popular model or size....
1 mm diameter. Angled 33 degrees. Round handle....
Medicine Products: